To bolster the in situ antitumor activity of tumor-resident PD-1+ICOS+CTLA4+CD4+ TILs, one could obviously also contemplate treating patients with cancer with anti–PD-1/anti-CTLA4 antagonist antibodies and/or anti-ICOS agonist antibodies. Here, PDCD1 is linked to neoplasm.